The Institute for Clinical and Economic Review (ICER) is in its third year of reviewing fair access to prescription drugs, but continues to face obstacles to doing a thorough assessment. Greater transparency is needed to make a clearer evaluation of consumers’ access to the drugs they are prescribed, the report – which deemed only two of 18 drugs included to be fairly priced and eligible for cost-sharing analysis – concludes.
Key Takeaways
-
The Institute for Clinical and Economic Review says insurers and other payers are meeting much of its recommendations for fair access to drugs, but more information...
In its 2023 Barriers to Fair Access report issued on 3 November, ICER notes that US insurers generally are meeting its criteria for cost-sharing, clinical eligibility and step therapy processes...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
